162 related articles for article (PubMed ID: 21401355)
1. Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients.
Solak Y; Atalay H; Guney I; Turkmen K; Kaya E; Turk S
Ren Fail; 2011; 33(3):307-11. PubMed ID: 21401355
[TBL] [Abstract][Full Text] [Related]
2. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
Atalay H; Solak Y; Acar K; Govec N; Turk S
Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
[TBL] [Abstract][Full Text] [Related]
3. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
5. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
[TBL] [Abstract][Full Text] [Related]
6. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
[TBL] [Abstract][Full Text] [Related]
7. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens.
Aronoff GR; Bennett WM; Blumenthal S; Charytan C; Pennell JP; Reed J; Rothstein M; Strom J; Wolfe A; Van Wyck D; Yee J;
Kidney Int; 2004 Sep; 66(3):1193-8. PubMed ID: 15327417
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
Goldstein SL; Morris D; Warady BA
Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
[TBL] [Abstract][Full Text] [Related]
11. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
12. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study.
Rostoker G; Griuncelli M; Loridon C; Couprie R; Benmaadi A; Bounhiol C; Roy M; Machado G; Janklewicz P; Drahi G; Dahan H; Cohen Y
Am J Med; 2012 Oct; 125(10):991-999.e1. PubMed ID: 22998881
[TBL] [Abstract][Full Text] [Related]
13. Safety of Intravenous Iron - Cosmofer and Monofer Therapy in Peritoneal Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients.
Sivakumar C; Jubb VM; Lamplugh A; Bhandari S
Perit Dial Int; 2019; 39(2):192-195. PubMed ID: 30858290
[TBL] [Abstract][Full Text] [Related]
14. A protocol for administering intravenous iron dextran in peritoneal dialysis patients.
Huff J
ANNA J; 1998 Aug; 25(4):419-23. PubMed ID: 9791315
[TBL] [Abstract][Full Text] [Related]
15. The safety of intravenous iron sucrose use in the elderly patient.
Reed J; Charytan C; Yee J
Consult Pharm; 2007 Mar; 22(3):230-8. PubMed ID: 17658969
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients.
Schaller G; Scheiber-Mojdehkar B; Wolzt M; Puttinger H; Mittermayer F; Hörl WH; Födinger M; Sunder-Plassmann G; Vychytil A
Kidney Int; 2005 Dec; 68(6):2814-22. PubMed ID: 16316358
[TBL] [Abstract][Full Text] [Related]
17. Trends in intravenous iron use among dialysis patients in the United States (1994-2002).
St Peter WL; Obrador GT; Roberts TL; Collins AJ
Am J Kidney Dis; 2005 Oct; 46(4):650-60. PubMed ID: 16183420
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight iron dextran in the management of renal anaemia in patients on haemodialysis--the IDIRA Study.
Rath T; Florschütz K; Kalb K; Rothenpieler U; Schletter J; Seeger W; Zinn S
Nephron Clin Pract; 2010; 114(1):c81-8. PubMed ID: 19887827
[TBL] [Abstract][Full Text] [Related]
19. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
20. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]